- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ozempic side effects 'well-known', Novo Nordisk argues
Novo Nordisk has refuted a Louisiana woman’s claim that her doctors weren’t properly warned of the side effects of the company’s blockbuster drug Ozempic, saying the vomiting and pain she alleged to have experienced are documented side effects included on the drug's label.
The Danish drugmaker filed a motion to dismiss Jaclyn Bjorklund’s lawsuit against the company on Friday in Louisiana federal court. Bjorklund said that while taking the drug for Type 2 Diabetes she developed gastroparesis, a slowdown in the emptying of the stomach into the small intestine, that led to her vomiting and pain.
The company in its motion to dismiss said the delay is actually part of how the drug works to improve blood sugar management. It also said that her symptoms were “extensively discussed” on the U.S. Food and Drug Administration’s approved label for the drug. Novo further argued that the Louisiana law Bjorklund cites in her lawsuit doesn't require physicians to be warned "about known risks such as the well-known side effects of Ozempic and Mounjaro she claims to have experienced."
Bjorklund’s attorneys at Morgan & Morgan did not immediately respond to requests for comment about Novo Nordisk’s filing. Attorneys for Novo Nordisk directed a request for comment to the company, which did not respond.
Court records show Bjorklund was one of the first people to sue Novo Nordisk about the side effects associated with Ozempic, which is among several drugs originally developed to help treat diabetes that have boomed in popularity because of their effectiveness in helping with weight loss. At least two similar lawsuits are pending, one in Louisiana federal court and one in Pennsylvania federal court, records show.
Morgan & Morgan, which is representing Bjorklund, and several other plaintiffs’ firms said they are investigating other claims by consumers alleging adverse effects from the drugs.
Novo makes Ozempic and Wegovy, a version of the drug that is specific for weight loss, and Eli Lilly makes diabetes drug Mounjaro.
Bjorklund, who filed her lawsuit in August claiming the companies downplayed the severity of the side effects, sued both Novo Nordisk and Eli Lilly, saying she took Ozempic and Mounjaro before experiencing the severe vomiting and pain that sent her to the hospital and also caused her to lose teeth.
Eli Lilly’s motion to dismiss, filed in October, claims the severe problems Bjorklund said she experienced began before she took Mounjaro. The company also argues that the symptoms she described are known and described in the drug’s label.
A spokesperson for Eli Lilly said the lawsuit lacks merit.
The case is Jaclyn Bjorklund v. Novo Nordisk, U.S. District Court for the Western District of Louisiana, No. 2:23-cv-01020.
For Bjorklund: Rene Rocha, Mike Morgan, Jonathan Sedgh, Josh Autry and Paul Pennock of Morgan & Morgan
For Novo Nordisk: Paige Sensenbrenner and Diana Cole Surprenant of Adams and Reese; and Loren Brown of DLA Piper
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751